PUBLISHER: Allied Market Research | PRODUCT CODE: 1365616
PUBLISHER: Allied Market Research | PRODUCT CODE: 1365616
According to a new report published by Allied Market Research, titled, "Antiplatelet Market," The antiplatelet market was valued at $3.8 billion in 2022, and is estimated to reach $5.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.
Platelets play a crucial role in hemostasis, the process that stops bleeding after an injury. When a blood vessel is damaged, platelets adhere to the site and aggregate together, forming a clot that helps seal the injury. However, in certain medical conditions, such as atherosclerosis or irregular heart rhythms, blood clots can form within blood vessels inappropriately, leading to blockages that may result in heart attacks or strokes. Antiplatelet drugs work by interfering with different steps in the platelet activation and aggregation process. Some commonly used antiplatelet medications include aspirin, clopidogrel, ticagrelor, and prasugrel. These drugs inhibit platelet activation by blocking specific receptors or enzymes involved in the clotting pathway.
The antiplatelets market is driven by factors such as the increase in prevalence of cardiovascular diseases, such as heart attacks and stroke that drives the demand for antiplatelet drugs as a preventive and treatment measure thereby propelling the market growth. For instance, according to the American Association, the prevalence of stroke in 2020 was 89.1 million people across the globe. In addition, the ischemic stroke was 68.2 million, that of intracerebral hemorrhage was 18.9 million, and that of subarachnoid hemorrhage was 8.1 million across the globe. Thus, rise in the cases of cardiovascular diseases drives the demand for antiplatelet drugs and propels the market growth.
In addition, ongoing R&D efforts in the field of antiplatelet drugs lead to the discovery of novel agents with enhanced efficacy and safety profiles. The introduction of new and improved drugs stimulates market growth and attracts investment in the sector. For instance, Lee's Pharmaceutical Limited is conducting a phase 1 clinical trial to investigate the tolerability, safety, and pharmacokinetics of Anfibatate.
Furthermore, percutaneous coronary intervention (PCI), commonly known as angioplasty, is a surgical procedure used to treat coronary artery disease. Antiplatelet medications play a crucial role in PCI procedures, both during and after the intervention. Thus, the surge in usage of antiplatelet drugs in percutaneous coronary intervention contributes to the expansion of the antiplatelet market.
The antiplatelet market is segmented into drug class, route of administration, distribution channel, and region. As per drug class, the market is segregated into adenosine diphosphate (ADP) receptor inhibitors, irreversible inhibitors cyclooxygenase, and others. By route of administration, it is categorized into oral and injectable. Depending on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the antiplatelet market are AstraZeneca plc, Bayer AG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Cipla Ltd., Otsuka Pharmaceutical Co., Ltd., Lupin, Sanofi S.A., Daiichi Sankyo Company Limited, and Chiesi Farmaceutici S.p.A. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)